Welcome to our dedicated page for Orasure Tech news (Ticker: OSUR), a resource for investors and traders seeking the latest updates and insights on Orasure Tech stock.
OraSure Technologies, Inc. (NASDAQ: OSUR) is a medical devices company focused on point-of-need and home diagnostic tests and sample management solutions. The OraSure news stream on this page highlights company announcements, financial updates, product milestones, governance changes, and shareholder developments that shape the OSUR investment story.
News coverage commonly includes quarterly and year-to-date financial results, where OraSure reports net revenues, gross margins, operating performance, and the mix of diagnostics, sample management solutions, COVID-19 diagnostics, risk assessment testing, molecular services, and non-product revenues. Earnings releases also discuss core business trends, cash and cash equivalents, and share repurchase activity, providing context on the company’s financial condition and capital allocation.
Investors and industry followers can also track product and innovation milestones, such as FDA submissions for the Sherlock rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) and the Colli-Pee at-home urine collection device for sexually transmitted infections. Additional updates may cover launches of research-use products like HEMAcollect PROTEIN, agreements with partners such as GeneDx, and participation in initiatives like the ENDO1000 project.
Governance and corporate developments feature prominently in OraSure news. Recent items include board refreshment, the appointment of new independent directors, changes in board leadership, and the hiring of senior executives such as the Chief Commercial Officer. News also documents shareholder engagement, including communications from Altai Capital Management regarding board nominations and perspectives on company performance and strategy.
By following this OSUR news page, readers can review a chronological record of OraSure’s press releases and related items, covering earnings, product pipeline progress, strategic initiatives, board composition, and shareholder actions, all drawn from official company and partner announcements.
OraSure Technologies (NASDAQ: OSUR) confirmed on Dec 17, 2025 that activist investor Altai Capital intends to nominate two director candidates, including founder Rishi Bajaj, for election at the 2026 annual meeting. The company said its Board evaluated Mr. Bajaj and declined to appoint him, has engaged with Altai, and that shareholders are not required to take action now.
OraSure highlighted corporate actions and financials: $216 million cash on hand as of Sept 30, 2025 with no debt, a $40 million share repurchase program, recent Board refresh (seven departures, three additions), and operational steps to improve margins.
Summary not available.
OraSure Technologies (NASDAQ: OSUR) will participate in the Stephens Annual Investment Conference on Wednesday, November 19, 2025. The company’s session includes a Q&A at 10:00 a.m. CT.
A live webcast and replay of the Q&A will be available on the company’s investor relations events page at https://orasure.gcs-web.com/events-and-presentations.
OraSure Technologies (NASDAQ: OSUR) reported Q3 2025 results for the quarter ended September 30, 2025: total revenue $27.1M (down 32% YoY) and core revenue $27.0M (down 25% YoY). Diagnostics declined 34% to $14.5M and Sample Management fell 20% to $10.3M. GAAP gross margin was 43.5%; operating loss was $16.1M and net loss was $13.7M. Cash and cash equivalents were $216M at Sept 30, 2025. The company deployed $5M to repurchase ~1.5M shares in Q3 and signed a definitive agreement to acquire BioMedomics (adds SickleSCAN rapid test). Guidance: Q4 2025 revenue of $25M–$28M.
OraSure (NASDAQ: OSUR) will report its third quarter 2025 financial results and host a conference call at 5:00 p.m. ET on November 5, 2025. A live webcast will be available on the company investor relations site at https://orasure.gcs-web.com/events-and-presentations. Participants are asked to register and access the webcast at least 10 minutes prior to the call. The webcast will be archived on the investor relations page shortly after the call and will remain available for approximately one year.
OraSure Technologies (NASDAQ: OSUR) announced the appointment of Steven K. Boyd to its Board of Directors as a Class II director, effective October 28, 2025. The company also appointed Jack Kenny as Board Chair and said Mara Aspinall will step down after more than eight years of service.
OraSure said the board changes are part of ongoing refreshment: the board now has seven directors, six independent, and three new independent directors added in the past three years. The release highlights strengthened balance sheet, improved profitability and cash flow, returned capital to shareholders, and a focus on diagnostics and sample management growth.
OraSure Technologies (NASDAQ: OSUR) reported Q2 2025 financial results showing significant revenue declines. Total net revenues decreased 43% to $31.2 million from $54.3 million in Q2 2024, primarily due to reduced COVID-19 revenues. Core revenues declined 5% to $30.8 million, while Diagnostics revenues increased 3% to $19.2 million.
The company reported a GAAP operating loss of $18.0 million compared to a $2.7 million loss in Q2 2024. Gross margin decreased to 42.1% from 45.4% year-over-year. Cash position remains strong at $235 million. The company repurchased 1.8 million shares for $5 million during Q2 and expects Q3 2025 revenues between $27-30 million.
OraSure Technologies (NASDAQ: OSUR), a leader in point-of-need diagnostics and sample management solutions, has appointed Anne Messing as Chief Commercial Officer. Messing brings over 25 years of commercial leadership experience in healthcare, including significant roles at Becton Dickinson, Danaher, and Quest Diagnostics.
In her new role, Messing will oversee Sales, Marketing, Strategic Alliances, and Product Management. Her background includes serving as VP and General Manager of BD Biosciences' U.S. Region, where she drove significant sales growth. She holds a BS in Medical Technology and an MS in Administration, with early career experience as a certified medical technologist.
OraSure Technologies (NASDAQ: OSUR) has scheduled its second quarter 2025 earnings conference call for August 5, 2025, at 5:00 PM ET. The company will discuss Q2 2025 financial results and business developments during the call.
Investors can access the webcast through OraSure's investor relations website. The webcast will be archived and available for approximately one year after the call. Participants who wish to ask questions during the call must pre-register through the provided link to receive access details.
OraSure Technologies (NASDAQ: OSUR) has launched HEMAcollect™●PROTEIN, a novel blood collection device designed for proteomic research. The product, developed by subsidiary DNA Genotek, features an evacuated blood collection tube with proprietary stabilizing technology that can preserve plasma proteins in whole blood for up to seven days at ambient temperature.
The device, powered by ProteoPrecision™ technology, minimizes hemolysis and platelet activation, ensuring sample integrity. It is compatible with various proteomic technologies including mass spectrometry, immunoassays, and high-throughput affinity-based platforms. The product aims to support research applications across multiple fields including oncology, neurology, cardiology, and metabolic disorders.